Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The medical landscape for chronic rhinosinusitis is rapidly advancing, with new treatments offering hope for improved quality of life for patients. As pharmaceutical companies race to develop ...

) has been revised to $44.37 / share. This is a decrease of 10.31% from the prior estimate of $49.47 dated March 25, 2026. The price target is an average of many targets provided by analysts. The ...

Shares of inflammatory disease biotech Upstream Bio, Inc. (UPB) have rallied by roughly 60% since reporting potentially best-in-class data for its asset verekitug in a Phase 2 trial in early September ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Pack your swimsuits and join the University Program Board (UPB) on the evening of Feb. 28 for the annual Kalahari trip! UPB has reserved the entire indoor waterpark exclusively for CWRU students.

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for ...